Back to All NewsFDA Clears CoolSculpting for Treatment of ‘Double Chin’
Posted By American Med Spa Association, Monday, February 26, 2018
Share
The U.S. Food and Drug Administration has cleared CoolSculpting as the first and only non-surgical fat reduction technology for use to improve the appearance of lax tissue and submental fat treatments, or "double chin," according to Allergan.
“Allergan is committed to advancing innovation for CoolSculpting to meet the needs of patients seeking non-invasive aesthetic treatments,” said David Nicholson, chief research and development officer at Allergan. “A 2017 American Society for Dermatologic Surgery (ASDS) survey revealed that 73% of patients are bothered by excess fat under the chin.2 We are pleased this patient concern can successfully be addressed by CoolSculpting through a non-invasive approach, and furthermore improve the appearance of lax tissue in the treated area.”
Read more at Skin Inc >>
“Allergan is committed to advancing innovation for CoolSculpting to meet the needs of patients seeking non-invasive aesthetic treatments,” said David Nicholson, chief research and development officer at Allergan. “A 2017 American Society for Dermatologic Surgery (ASDS) survey revealed that 73% of patients are bothered by excess fat under the chin.2 We are pleased this patient concern can successfully be addressed by CoolSculpting through a non-invasive approach, and furthermore improve the appearance of lax tissue in the treated area.”
Read more at Skin Inc >>
